Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis

Respirology

Volumn 22, Issue 6, 2017, Pages 1084-1092

  Tarrant, Benjamin J ^a,b   Le Maitre, Caitlin ^a   Romero, Lorena ^c   Steward, Ranjana ^a   Button, Brenda M ^a,d   Thompson, Bruce R ^a,d   Holland, Anne E ^a,b  

^a Alfred Health ^*  (Australia)

^b LA TROBE UNIVERSITY   (Australia)

^c AMREPAlfred   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

expectorants; humans; lung diseases; respiratory function tests; sputum

Indexed keywords

ACETYLCYSTEINE; DORNASE ALFA; MANNITOL; MESNA; SODIUM CHLORIDE; DEOXYRIBONUCLEASE I; EXPECTORANT AGENT; RECOMBINANT PROTEIN;

ASTHMA; BRONCHIECTASIS; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CHEST TIGHTNESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DYSPNEA; FLU LIKE SYNDROME; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOSPITALIZATION; HUMAN; INFLAMMATION; LENGTH OF STAY; LUNG FUNCTION; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SPIROMETRY; SPUTUM; STOMACH DISCOMFORT; SYSTEMATIC REVIEW; UPPER RESPIRATORY TRACT CONGESTION; WHEEZING; CHRONIC DISEASE; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASE; MUCOCILIARY CLEARANCE; PATHOPHYSIOLOGY; RECURRENT DISEASE; VITAL CAPACITY;

ACETYLCYSTEINE; ADMINISTRATION, INHALATION; BRONCHIECTASIS; CHRONIC DISEASE; DEOXYRIBONUCLEASE I; EXPECTORANTS; FORCED EXPIRATORY VOLUME; HUMANS; LUNG DISEASES; MANNITOL; MESNA; MUCOCILIARY CLEARANCE; QUALITY OF LIFE; RECOMBINANT PROTEINS; SALINE SOLUTION, HYPERTONIC; SYMPTOM FLARE UP; VITAL CAPACITY;

EID: 85017498124     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.13047     Document Type: Review

References (42)

1. Rubin BK. Mucolytics, expectorants, and mucokinetic medications. Respir. Care 2007; 52: 859–65.
2. Jones AP, Wallis C. Dornase alfa for cystic fibrosis. Cochrane Database Syst. Rev. 2010; (3): CD001127.
3. Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst. Rev. 2009; (2): CD001506.
4. Aitken ML, Bellon G, De Boeck K, Flume PA, Fox HG, Geller DE, Haarman EG, Hebestreit HU, Lapey A, Schou IM et al.; CF302 Investigators. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am. J. Respir. Crit. Care Med. 2012; 185: 645–52.
5. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]. The Cochrane Collaboration, 2011.
6. Bilton D, Daviskas E, Anderson SD, Kolbe J, King G, Stirling RG, Thompson BR, Milne D, Charlton B; B301 Investigators. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013; 144: 215–25.
7. Bilton D, Tino G, Barker AF, Chambers DC, De Soyza A, Dupont LJ, O'Dochartaigh C, van Haren EH, Vidal LO, Welte T et al.; B-305 Study Investigators. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax 2014; 69: 1073–9.
8. Cato A, Goldstein I, Millman M. A double-blind parallel study of acetylcysteine-isoproterenol and saline-isoproterenol in patients with chronic obstructive lung disease. J. Int. Med. Res. 1977; 5: 175–83.
9. Clarke SW, Lopez-Vidriero MT, Pavia D, Thomson ML. The effect of sodium 2-mercapto-ethane sulphonate and hypertonic saline aerosols on bronchial clearance in chronic bronchitis. Br. J. Clin. Pharmacol. 1979; 7: 39–44.
10. Daviskas E, Anderson SD, Eberl S, Young IH. Beneficial effect of inhaled mannitol and cough in asthmatics with mucociliary dysfunction. Respir. Med. 2010; 104: 1645–53.
11. Daviskas E, Anderson SD, Young IH. Effect of mannitol and repetitive coughing on the sputum properties in bronchiectasis. Respir. Med. 2010; 104: 371–7.
12. Daviskas E, Anderson SD, Gonda I, Eberl S, Meikle S, Seale JP, Bautovich G. Inhalation of hypertonic saline aerosol enhances mucociliary clearance in asthmatic and healthy subjects. Eur. Respir. J. 1996; 9: 725–32.
13. Daviskas E, Anderson SD, Eberl S, Chan HK, Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 1999; 159: 1843–8.
14. Daviskas E, Anderson SD, Eberl S, Young IH. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur. Respir. J. 2008; 31: 765–72.
15. Dueholm M, Nielsen C, Thorshauge H, Evald T, Hansen NC, Madsen HD, Maltbaek N. N-acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi-centre study. Respir. Med. 1992; 86: 89–92.
16. Dulfano MJ, Glass P. An effective mucolytic aerosol in chronic bronchitis. JAMA 1969; 207: 1310–4.
17. Grater WC, Cato A. Double-blind study of acetylcysteine-isoproterenol and saline-isoproterenol in non-hospitalized patients with asthma. Curr. Ther. Res. Clin. Exp. 1973; 15: 660–71.
18. Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir. Med. 2005; 99: 27–31.
19. Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir. Med. 2011; 105: 1831–5.
20. Khan SY, O'Driscoll BR. Is nebulized saline a placebo in COPD? BMC Pulm. Med. 2004; 4: 9.
21. May O, Hansen NC. Comparison of terbutaline, isotonic saline, ambient air and non-treatment in patients with reversible chronic airway obstruction. Eur. Respir. J. 1988; 1: 527–30.
22. Morandini GC, Finiguerra M, Conti P, Bernocchi D, Manini G. Treatment of chronic bronchitis. Combined therapy with sustained-release theophylline (Teonova) and a mucoactive drug sobrerol (Sobrepin). Clin. Trials 1989; 26: 163–74.
23. Nicolson CH, Stirling RG, Borg BM, Button BM, Wilson JW, Holland AE. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir. Med. 2012; 106: 661–7.
24. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998; 113: 1329–34.
25. Paez PN, Miller WF. Surface active agents in sputum evacuation: a blind comparison with normal saline solution and distilled water. Chest 1971; 60: 312–7.
26. Poole PJ, Brodie SM, Stewart JM, Black PN. The effects of nebulised isotonic saline and terbutaline on breathlessness in severe chronic obstructive pulmonary disease (COPD). Aust. N. Z. J. Med. 1998; 28: 322–6.
27. Pulle DF, Glass P, Dulfano MJ. A controlled study of the safety and efficiency of acetylcysteine-isoproterenol combination. Curr. Ther. Res. Clin. Exp. 1970; 12: 485–92.
28. Sabath LD, Sasahara AA, Burleson VA. Evaluation of a new mucolytic agent. Dis. Chest 1966; 50: 47–56.
29. Schreiber J, Bohnsteen B, Rosahl W. Influence of mucolytic therapy on respiratory mechanics in patients with chronic obstructive pulmonary disease. Eur. J. Med. Res. 2002; 7: 98–102.
30. Silverman RA, Foley F, Dalipi R, Kline M, Lesser M. The use of rhDNAse in severely ill, non-intubated adult asthmatics refractory to bronchodilators: a pilot study. Respir. Med. 2012; 106: 1096–102.
31. Steen SN, Ziment I, Freeman D, Thomas JS. Evaluation of a new mucolytic drug. Clin. Pharmacol. Ther. 1974; 16: 58–62.
32. Stiksa G, Nemcek K, Melin S. Effects of inhaled N-acetylcysteine in combination with terbutaline. Eur. J. Respir. Dis. 1984; 65: 278–82.
33. Sutton PPGH, Innes N, Davidson J, Smith FW, Legge JS. Use of nebulised saline and nebulised terbutaline as an adjunct to chest physiotherapy. Thorax 1988; 43: 57–60.
34. Valderramas SR, Atallah AN. Effectiveness and safety of hypertonic saline inhalation combined with exercise training in patients with chronic obstructive pulmonary disease: a randomized trial. Respir. Care 2009; 54: 327–33.
35. Wills PJ, Wodehouse T, Corkery K, Mallon K, Wilson R, Cole PJ. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. Am. J. Respir. Crit. Care Med. 1996; 154: 413–7.
36. Review Manager (RevMan) [Computer Program]. Version 5.3. Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
37. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005; 2: 75–9.
38. Raj AA, Pavord DI, Birring SS. Clinical cough IV: what is the minimal important difference for the Leicester Cough Questionnaire? Handb. Exp. Pharmacol. 2009; 187: 311–20.
39. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65: i1–58.
40. National Clinical Guideline Centre. Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. London, National Clinical Guideline Centre, 2010.
41. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2016 Available from URL: http://www.ginasthma.org.
42. Heijerman H, Westerman E, Conway S, Touw D, Doring G. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J. Cyst. Fibros. 2009; 8: 295–315.